Clinical predictors of latanoprost treatment effect

Journal of Glaucoma

Volumn 14, Issue 4, 2005, Pages 260-263

  Bayer, Atilla ^a,b   Henderer, Jeffrey D ^b   Kwak, Terry ^b   Myers, Jonathan ^b   Fontanarosa, Joann ^b   Spaeth, George L ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Drug efficacy; Intraocular pressure reduction; Latanoprost effect

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST;

ADULT; AGE; AGED; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OPTIC DISK; OPTIC DISK DAMAGE LIKELIHOOD SCALE STAGE; PAPILLEDEMA; PREDICTION; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHILD; CLINICAL TRIALS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 22544470568     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000169382.67486.2e     Document Type: Review

References (25)

1. Rulo AH, Greve EL, Geijssen HC, et al. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276-1282.
2. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126-137.
3. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106:550-555.
4. Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS. 1999;3:33-39.
5. Vetrugno M, Maino A, Quaranta GM, et al. A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy. Eur J Ophthalmol. 2000;10:205-211.
6. Altuna JC, Greenfield DS, Wand M, et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J Glaucoma. 1999;8:199-203.
7. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.
8. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
9. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
10. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279-286.
11. Bayer A, Harasymowycz P, Henderer JD, et al. Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage. Am J Ophthalmol. 2002;133:758-763.
12. Urner-Bloch U, Bischoff P. [Long-term therapy with timolol for three years (author's transi)]. Klin Monatsbl Augenheilkd. 1981;179:45-47.
13. Tamada Y, Taniguchi T, Murase H, et al. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2001;17:19-25.
14. Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group. Clin Ther. 2000;22:388-399.
15. Hedman K, Aim A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95-104.
16. Camras CB, Aim A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916-1924.
17. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.
18. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662-665.
19. Susanna R Jr, Giampani J Jr, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259-263.
20. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol. 2000;84:579-582.
21. Polo V, Larrosa JM, Gomez ML, et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand. 2001;79:6-9.
22. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109:307-314; discussion 14-15.
23. Mandic Z, Bojic L, Novak-Laus K, et al. Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma. Coll Antropol. 2002;26:595-600.
24. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
25. Realini T, Fechtner RD, Atreides SP, et al. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology. 2004;111:421-426.